[go: up one dir, main page]

NO20024172L - Vaksine - Google Patents

Vaksine

Info

Publication number
NO20024172L
NO20024172L NO20024172A NO20024172A NO20024172L NO 20024172 L NO20024172 L NO 20024172L NO 20024172 A NO20024172 A NO 20024172A NO 20024172 A NO20024172 A NO 20024172A NO 20024172 L NO20024172 L NO 20024172L
Authority
NO
Norway
Prior art keywords
vaccine
Prior art date
Application number
NO20024172A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024172D0 (no
Inventor
Jean-Charles Fruchart
Philippe Monteyne
Remi Palmantier
Marcelle Paulette Van Mechelen
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005240A external-priority patent/GB0005240D0/en
Priority claimed from GB0022005A external-priority patent/GB0022005D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO20024172D0 publication Critical patent/NO20024172D0/no
Publication of NO20024172L publication Critical patent/NO20024172L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20024172A 2000-03-03 2002-09-02 Vaksine NO20024172L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005240A GB0005240D0 (en) 2000-03-03 2000-03-03 Vaccine
GB0022005A GB0022005D0 (en) 2000-09-07 2000-09-07 Vaccine
PCT/EP2001/002326 WO2001064008A2 (fr) 2000-03-03 2001-03-01 Vaccins

Publications (2)

Publication Number Publication Date
NO20024172D0 NO20024172D0 (no) 2002-09-02
NO20024172L true NO20024172L (no) 2002-11-01

Family

ID=26243793

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024172A NO20024172L (no) 2000-03-03 2002-09-02 Vaksine

Country Status (19)

Country Link
US (1) US20030165503A1 (fr)
EP (1) EP1267908B1 (fr)
JP (1) JP2003525883A (fr)
KR (1) KR20020079983A (fr)
CN (1) CN1418106A (fr)
AR (1) AR027591A1 (fr)
AT (1) ATE265860T1 (fr)
AU (1) AU2001246493A1 (fr)
BR (1) BR0108924A (fr)
CA (1) CA2401755A1 (fr)
CZ (1) CZ20022971A3 (fr)
DE (1) DE60103137T2 (fr)
ES (1) ES2219517T3 (fr)
HU (1) HUP0300099A3 (fr)
IL (1) IL151355A0 (fr)
MX (1) MXPA02008616A (fr)
NO (1) NO20024172L (fr)
PL (1) PL365424A1 (fr)
WO (1) WO2001064008A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
EE200200238A (et) * 2000-09-04 2003-06-16 Kim Hyo-Joon Apolipoproteiin B-100 epitoobi mimeetpeptiidid, nende konkatemeer ja modifitseeritud peptiidid ningneid sisaldavad vaktsiinikompositsioonid
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
WO2002098919A2 (fr) * 2001-06-05 2002-12-12 Genfit Nouvelle methode de mesure de apo ciii dans des particules contenant apo b et des particules exemptes de apo b
CA2460787A1 (fr) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention et traitement de la restenose par l'administration locale d'un medicament
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
AU2003267905B2 (en) * 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
GB0305793D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305794D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB2404981A (en) * 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
EP1732383A4 (fr) 2004-04-06 2007-05-02 Cedars Sinai Medical Center Prevention et traitement des maladies vasculaires avec des vecteurs de virus associes aux adenovirus de recombinaison codant l'apolipoproteine a-i et l'apolipoproteine a-i milano
CN101166981A (zh) * 2005-04-11 2008-04-23 阿斯利康(瑞典)有限公司 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒
WO2009152493A2 (fr) * 2008-06-13 2009-12-17 The General Hospital Corporation Utilisation d’apoliprotéines pour diminuer l’inflammation
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
CN103501806A (zh) 2010-11-12 2014-01-08 赛达斯西奈医疗中心 用于治疗和/或预防动脉瘤的免疫调节方法和系统
CA2817543A1 (fr) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Procedes et systemes immunomodulateurs pour le traitement et/ou la prevention de l'hypertension
US9783600B2 (en) 2013-02-25 2017-10-10 Imbp Holding, Llc Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN114085283A (zh) * 2015-05-19 2022-02-25 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
CN106810606A (zh) * 2015-11-27 2017-06-09 西藏自治区人民医院 一种载脂蛋白c-ⅲ抗原多肽及其多克隆抗体的制备与应用
US20190201540A1 (en) * 2016-05-24 2019-07-04 Stc Unm Immunogens, compositions, and methods for treating dyslipidemia
CA3030099A1 (fr) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anticorps anti-apoc3 et leurs methodes d'utilisation
CN106519007B (zh) * 2016-12-12 2019-07-02 王家祥 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
BR112020008514A2 (pt) 2017-10-31 2020-10-20 Staten Biotechnology B.V. anticorpos anti-apoc3 e métodos de uso dos mesmos
CN110590937A (zh) * 2018-06-13 2019-12-20 杨宝田 一种人血载脂蛋白a1制品的制备方法及应用
US20230134067A1 (en) * 2020-07-22 2023-05-04 3H Bio. Co., Ltd. A peptide used for immunotherapeutics
WO2022136466A1 (fr) 2020-12-23 2022-06-30 Argonaute RNA Limited Traitement d'une maladie cardiovasculaire
JP2024531728A (ja) 2021-09-14 2024-08-29 アルゴノート アールエヌエー リミテッド 心血管疾患の処置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239631A4 (fr) * 1985-10-04 1989-01-12 Biotech Res Partners Ltd Apolipoproteines recombinantes et procedes.
WO1993000443A1 (fr) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification d'apolipoproteine e recombinante tiree de bacteries
IL104015A0 (en) * 1992-12-07 1993-05-13 Doina International Ltd P Method for immunization of mammals against atherosclerosis and pharmaceutical compositions for obtaining said immunization
CA2274241C (fr) * 1996-08-23 2003-05-27 Esperion Therapeutics Inc. Technique de purification d'alipoproteine a ou e provenant de plasma sanguin humain
US6492185B1 (en) * 1998-01-16 2002-12-10 Abbott Laboratories Immunoassay for detection of very low density lipoprotein and antibodies useful therefor
FR2776388B1 (fr) * 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
FR2780512B1 (fr) * 1998-06-25 2003-10-17 Lipha Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique

Also Published As

Publication number Publication date
CZ20022971A3 (cs) 2003-02-12
EP1267908B1 (fr) 2004-05-06
WO2001064008A2 (fr) 2001-09-07
PL365424A1 (en) 2005-01-10
JP2003525883A (ja) 2003-09-02
CA2401755A1 (fr) 2001-09-07
BR0108924A (pt) 2003-04-29
HUP0300099A3 (en) 2004-10-28
US20030165503A1 (en) 2003-09-04
EP1267908A1 (fr) 2003-01-02
ATE265860T1 (de) 2004-05-15
NO20024172D0 (no) 2002-09-02
CN1418106A (zh) 2003-05-14
AU2001246493A1 (en) 2001-09-12
AR027591A1 (es) 2003-04-02
MXPA02008616A (es) 2003-02-24
DE60103137D1 (de) 2004-06-09
KR20020079983A (ko) 2002-10-21
WO2001064008A3 (fr) 2002-02-14
ES2219517T3 (es) 2004-12-01
HUP0300099A2 (en) 2003-05-28
IL151355A0 (en) 2003-04-10
DE60103137T2 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
NO20031483D0 (no) Vaksine
NO20024172D0 (no) Vaksine
PL363005A1 (pl) Szczepionki
NO20026175L (no) Vaksinesammensetning
NO20031705L (no) Vaksiner
NO20014322L (no) Vaksine
DE60121916D1 (de) Bohrloch-densitometer
ATE290000T1 (de) Muscarinagonisten
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DK1427444T3 (da) West-nil-vaccine
NO20012438L (no) Strålingseffektutjevner
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763L (no) Vaksine
NO20033882L (no) Vaksine
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
DE60135277D1 (de) Elektrolumineszenselement
NO20024322L (no) Sekvens
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
ATE476423T1 (de) Benzoylpyridazine
AR027982A1 (es) Aril- y heteroarilsulfonatos
ATA7092001A (de) Skibindungseinstellgerät
AT500246B8 (de) Chokerring

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application